BOS MANCHESTER 2023

28th and 29th of November at Manchester Central



Programme

Day 1: 28th November

08:45 - 10:00	REGISTRATION & SPEEDY PARTNERING (10 MIN PARTNERING SLOTS)
10.00 – 12.00	OUTSOURCING PROCESS & STRATEGIES Chair: Dr Joan Herbert, VP of Business Development , Medicines for Malaria Venture
10:00	DRIVING SUSTAINABILITY IMPROVEMENTS FROM OUTSOURCING PARTNERSHIPS Calum Cook, Lead Team Outsourcing Manager, AstraZeneca
10:30	CHALLENGES IN DEVELOPING AN EFFECTIVE CDMO OPERATING MODEL, AS THE ORGANISATION GROWS IN SIZE AND COMPLEXITY Dr Colm Campbell, Senior Director, Chemical Development & Manufacturing, BioMarin
1100	NAVIGATING A PATHWAY TO NEW CRO LAUNCH Dr Suzy Dilly, CEO, ValiRx
11:30	HOW TO DEVELOP A SAFE PROCESS WITH HAZARDOUS CHEMISTRY? Dr Jan Haller, R&D-Chemist, Axplora
11:45	LEVERAGING DEVELOPABILITY ASSESSMENTS TO ACCELERATE AND DE-RISK FORMULATION DEVELOPMENT Dr Mark Lawlor, Vice-President, Product Development, Pharmaron
12:00 - 13:30	LUNCH BREAK
13.30 – 15.30	TECHNICAL OPERATIONS OUTSOURCING Dr Paul Madeley, CEO, Synth-Isis
13:30	HARNESSING INNOVATIVE EXTERNAL CAPABILITIES TO EXPEDITE EARLY CHEMICAL DEVELOPMENT Andrew Stark, Senior Scientist, Technical Outsourcing, AstraZeneca
14:00	CMO/CRO SELECTION FOR AN EARLY STAGE BIOLOGICS COMPANY, PROCESS AND CHALLENGES Dr Paul Varley, SVP CMC Development, Alchemab
14:30	LIPOPHILICITY – CURRENT DRUG DISCOVERY LANDSCAPE AND CHROMATOGRAPHIC METHODS FOR ITS DETERMINATION Dr Magdalena Kierkowicz, Senior Scientist, UCB Pharma Ltd
15:00	ADDRESSING THE GROWING COMPLEXITY OF STERILE PRODUCT DEVELOPMENT Dr Iain MacGilp, Senior Director, Curia Scotland Ltd
15:15	USE OF MODELLING TO IMPROVE PROCESS UNDERSTANDING AND FACILITATE PROJECT DELIVERY Mr George Taylor, Chemistry Team Leader, Sai Life Sciences Limited
15:30	COFFEE BREAK
16.00 – 17.00	OUTSOURCING CASE STUDIES Chair: Prof Brian Cox, Emeritus Professor of Pharmaceutical Chemistry, B Cox Consulting Ltd
16:00	OPTIMIZING PROGRAM DELIVERY THROUGH CONTRACT RESEARCH ORGANIZATIONS AND THEIR SUB-CONTRACTORS Dr Stephane Haudac, Senior CMC Project and IP Manager, Destiny Pharma plc
16:20	UTILISING ADVANCED TECHNOLOGIES TO SUPPORT PRODUCT DEVELOPMENT THROUGH TO COMMERCIAL SUCCESS Dr Scott Wharry, Custom and Flow Chemistry Manager, Almac
16:40	HIGHLY COLLABORATIVE WORK TO SUPPORT MARKETED PRODUCTS Dr Craig S. Harris, CEO and Founder , CMC Innov Consulting
17:00 - 19:00	DRINKS RECEPTION & CANAPÉS

COMMUNITY FOR DISCOVERY & CMC OUTSOURCING PROFESSIONALS









08:00 -09:00	COFFEE & 1-TO-1 PARTNERING	

15:00 - 16:00 DRINKS RECEPTION AND CONFERENCE CLOSE

09.00 – 11.00	TECHNICAL OPERATIONS OUTSOURCING Chair: Dr Stella James, Executive Director, Business Development, BIONOW
09:00	HARNESSING AI TO EXPEDITE ANTIMALARIAL DRUG DISCOVERY Dr Paul Willis, Senior Director Drug Discovery, Medicines for Malaria Venture & Dr Thorsten Nowak, VP Medicinal Chemistry, Exscientia
09:30	SUSTAINABLE MANUFACTURING OF BMS-986278 LEVERAGING AN ERED/KRED BIOCATALYTIC CASCADE Dr Shane McKenna, Principal Scientist, Bristol Myers Squibb
10:00	DEVELOPMENT OF PHASE APPROPRIATE DRUG PRODUCTS AND MANAGEMENT OF THE CMC MINEFIELD IN AN OUTSOURCING ENVIRONMENT Dr Kreshnik Hoxha, Director of CMC and Clinical Supply Chain, Grey Wolf Therapeutics
10.20	AN INTRODUCTION TO CRAMSN: A ONE STOP SHOP CRO & CDMO SOLUTIONS PARTNER FOR YOUR CHEMISTRY NEEDS Mr Donald Charles Ross, Life Sciences Leader and Dr Vijayavitthal Mathad, Chief Operating Officer, CRAMSN Research Park, Private Limited
10.35	THE SPINOUT JOURNEY FROM DRUG REPURPOSING TO CLINICAL TRIALS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE Dr Farid Khan, CEO, PharmaKure
11:00	COFFEE BREAK
	COFFEE BREAK OUTSOURCING CASE STUDIES Chair: Ducan Judd, CEO, Awridian
	OUTSOURCING CASE STUDIES
11.30 – 12.30	OUTSOURCING CASE STUDIES Chair: Ducan Judd, CEO, Awridian ENHANCE: SCALING UP DEVELOPMENT OF NOVEL MERGO® FORMULATIONS VIA OPTIMISED SYNTHESIS AND HIGH-THROUGHPUT STRATEGIES
11.30 – 12.30 11:30	OUTSOURCING CASE STUDIES Chair: Ducan Judd, CEO, Awridian ENHANCE: SCALING UP DEVELOPMENT OF NOVEL MERGO® FORMULATIONS VIA OPTIMISED SYNTHESIS AND HIGH-THROUGHPUT STRATEGIES Dr Aleksandra Singh, R&D Oligonucleotide Synthesis Lead, Sixfold Bioscience NOVEL BICYCLIC DRUG PRODUCT DEVELOPMENT AND STERILE MANUFACTURE
11.30 – 12.30 11:30	OUTSOURCING CASE STUDIES Chair: Ducan Judd, CEO, Awridian ENHANCE: SCALING UP DEVELOPMENT OF NOVEL MERGO® FORMULATIONS VIA OPTIMISED SYNTHESIS AND HIGH-THROUGHPUT STRATEGIES Dr Aleksandra Singh, R&D Oligonucleotide Synthesis Lead, Sixfold Bioscience NOVEL BICYCLIC DRUG PRODUCT DEVELOPMENT AND STERILE MANUFACTURE Dr Jenifer Mains, Director, Formulation Science, Bicycle Therapeutics MANUFACTURING KNS366 FROM SPINOUT TO FIRST IN HUMAN STUDIES

